Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.
Copyright © 2011 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The Department of Radiation Oncology VU University Medical Center has a research agreement with Varian Medical Systems and BrainLAB AG.
| Benchmark | Comment |
|---|---|
| Is there equipoise amongst treating and referring physicians? | It is difficult to argue that there is equipoise or uncertainty given the local control data in favour of SABR. This now includes institutional, phase II, meta-analysis and population-based sources [5,6,11,13]. In a number of countries, SABR is now regarded as a standard of care for patients with medically inoperable peripheral early-stage NSCLC. |
| Is one treatment as convenient as the other? | This is not the case as SABR is typically delivered in 3-8 intermittent fractions and finished within 1-2.5 wk [6], whereas conventionally fractionated RT may require upwards of 20-30 daily fractions and take 4-6 wk or more to complete. More hypo-fractionated conventional treatments require up to 15 daily fractions that can be delivered in 3 wk [18]. The available data suggests that patient convenience and the efficacy and favourable toxicity associated with SABR may be key factors that influence treatment uptake in elderly patients with co-morbidity [11]. Furthermore recent advances in RT technology have enabled treatment times for each session of SABR to be shortened considerably in recent times [4]. |
| Do the two interventions represent equally effective use of constrained resources? | This is unlikely to be the case as modern conventionally delivered RT still requires image-guidance and it uses more treatment slots and a longer total time on the treatment machine (see above). Combined with an a priori lack of equipoise, this means that conventional treatment might actually use more resources for a less favourable outcome. Comparisons between the resources required for an established conventional lung RT service with those deployed early on in a lung SABR program (e.g., for treatment planning and quality assurance workflows) may be inappropriate, as substantial improvements in overall efficiency can be expected with SABR once experience increases and provided that the program is designed effectively. |
| Are there lessons from other clinical scenarios? | There are analogies to be drawn with localized prostate cancer, where no high-quality, RCT exists to support one active intervention over another [19]. There are other examples where a lack of randomized data to support one intervention over another, including for example surgery versus radiosurgery for brain metastases [20] has not hindered their widespread clinical use. |
| Are RCT the only way to assess lung SABR and the associated technological advances? | While some maintain that a RCT is the only way in which to truly evaluate an intervention, they can have many potential limitations including cost, concerns over general applicability of findings, insufficient power, the time taken to generate results and the risk that these will be redundant when they are reported [21]. A RCT may also not be the best way in which to assess technological advances [22], and it may be impractical or inappropriate when there is sufficient alternative evidence to support a treatment, for example lung SABR for medically inoperable early stage NSCLC, which is already standard of care in some countries. |
| Cancer type and stage | Patient group/Clinical scenario | Routine clinical use or suitable for a clinical study |
|---|---|---|
| Early-stage NSCLC | Medically operable patients or medically operable patients who decline surgery |
Routine clinical use |
| Medically operable patients | Clinical study | |
| Re-irradiation after full-dose conventional RT | Clinical study | |
| Stage IV NSCLC | Patients with 1-5 oligometastases, either following systemic chemotherapy or in those who decline or are unable to receive chemotherapy |
Clinical study |
| If no study then routine use in selected patients. | ||
| A prospective institutional, multi-center or national registry may be useful. |
||
| Patients with NSCLC and EGFR mutation | As above | |
| Concurrent SABR and systemic treatment (e.g., targeted therapy) |
Clinical study | |
| Maximal tumor debulking using SABR±other ablative interventions as part of a multi-modal management strategy |
Clinical study | |
| If no study then use may be justifiable in selected patients |
SABR, stereotactic ablative radiotherapy; NSCLC, non-small cell lung cancer; RT, radiotherapy; RCT, randomized controlled trial.
SABR, stereotactic ablative radiotherapy; NSCLC, non-small cell lung cancer; RT, radiotherapy; EGFR, epidermal growth factor receptor.
